← All trials
NCT04951349
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2021
- Primary completion
- May 30, 2021
- Completion date
- May 30, 2021
- First posted
- Jul 6, 2021
- Last posted
- Jul 6, 2021
- Enrollment
- 85
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Turn TherapeuticsLead sponsor
- University of Alabama, BirminghamCollaborator
- Hospital Modular - Covid-19Collaborator
- Hospital Santo TomasCollaborator
- Hospital Punta PacificaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.